

Supplementary Online Content

Hsu J, Patel SN, Wolfe J, et al. Effect of adjuvant topical dorzolamide-timolol vs placebo in neovascular age-related macular degeneration: a randomized clinical trial. *JAMA Ophthalmol*. Published online April 2, 2020. doi:10.1001/jamaophthalmol.2020.0724

eFigure 1. Distribution of changes in central subfoveal fluid height from the baseline visit


eFigure 2. Mean visual acuity at the baseline visit and subsequent three visits

eFigure 3. Mean change in visual acuity from the baseline visit


eTable. Adverse events summary

This supplementary material has been provided by the authors to give readers additional information about their work.


eFigure 1. Distribution of changes in central subfoveal fluid height from the baseline visit. *P* values were obtained using analysis of covariance, with adjustment for baseline central subfoveal fluid height and type of anti-vascular endothelial growth factor used. Error bars represent standard deviation. Topical dorzolamide-timolol (black) versus placebo (gray).



eFigure 2. Mean visual acuity at the baseline visit and subsequent three visits. Error bars represent standard deviation. Topical dorzolamide-timolol (black) versus placebo (gray).



eFigure 3. Mean change in visual acuity from the baseline visit. *P* values were obtained using analysis of covariance. Error bars represent standard deviation. Topical dorzolamide-timolol (black) versus placebo (gray).



eTable 1. Adverse events summary

	Dorzolamide- Timolol, No. (%) Total N = 27	Placebo, No. (%) Total N = 25
Related to treatment		
Eyelid swelling		1 (4)
Not related to treatment, but occurred during the study period		
Rectal bleeding	1 (4)	
Leg weakness		1 (4)